To induce EAU, C57BL/6 mice were immunized with a 200 µL emulsion of 150 µg human IRBP1–20 (GPTHLFQPSLVLDMAKVLLD, Hanhong, China) in an equal volume of complete Freund’s adjuvant (CFA, Sigma-Aldrich, St. Louis, MO, USA) containing 2.5 mg/mL Mycobacterium tuberculosis (strain 37RA) (Sigma-Aldrich, St. Louis, MO, USA) and 0.5 µg of Bordetella pertussis toxin (PTX, Sigma-Aldrich, St. Louis, MO, USA), as described in a previous study [36 (link)].
For treatment, EAU mice were intravitreally injected with mouse-recombinant IL-24 (200 ng in 2 µL) (R&D Systems, Minneapolis, MN, USA) into the left eye at the onset of disease. As a negative control, 2 µL of PBS was injected into the right eye. Eyes were examined by funduscopy at regular intervals using the Micron-IV retinal imaging system for small animals (Phoenix Research Laboratories, Pleasanton, CA, USA) and scored on a scale of 0–4, as described in previous study [37 (link)]. Experiments were terminated on day 6–8 after disease onset for eye collection.
For treatment, EAU mice were intravitreally injected with mouse-recombinant IL-24 (200 ng in 2 µL) (R&D Systems, Minneapolis, MN, USA) into the left eye at the onset of disease. As a negative control, 2 µL of PBS was injected into the right eye. Eyes were examined by funduscopy at regular intervals using the Micron-IV retinal imaging system for small animals (Phoenix Research Laboratories, Pleasanton, CA, USA) and scored on a scale of 0–4, as described in previous study [37 (link)]. Experiments were terminated on day 6–8 after disease onset for eye collection.
Free full text: Click here
